Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study

June 12, 2020 updated by: Claudia Spies

Despite large efforts trying to improve diagnostic and therapy of sepsis have been made over the last decade (e.g. initiation of the Surviving Sepsis Campaign, defining evidence based sepsis therapy bundles) the mortality of septic shock remains high and causes high socioeconomical burden of disease.

The purpose of this pilot study is to evaluate the design and conduct of a projected full scale clinical trial.

Study Overview

Status

Completed

Conditions

Detailed Description

A functional clock is required for induction of several proinflammatory genes, not shown in septic patient settings, yet.

Clock genes are involved in modulating the activity of several transcription factors that are important regulators of immune functions (e.g. HIF1-α, STAT1, STAT3, and NF-κB) (Bellet MM et al., 2013).

Furthermore, polymorphisms such as rs7221412, a common polymorphism near period homolog 1 (PER1), was associated with the timing of activity rhythms and also showed a suggestive time-dependent relationship with both cerebral cortex and monocytes PER1 expression and an association with time of death (Lim ASP et al., 2012).

This explorative project is a pilot study. First data are generated for the assessment of the circadian system in patients with septic shock.

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, 13353
        • Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte and Campus Virchow - Klinikum, Charité- Universitätsmedizin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Critically ill patients with septic shock

Description

Inclusion Criteria:

  • Male and female patients with age 18 years and above,
  • Patient at intensive care units (8i, 9i and 1i at Charité - University Medicine Berlin , Campus Virchow- Klinikum),
  • Septic shock (ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine) consensus definitions) AND Norepinephrine dosage of >0.3 μg/kg/min for at least 2 hours

Exclusion Criteria:

  • Pregnant or lactating female patient,
  • Participation in another interventional study (30 days before study inclusion and during study participation),
  • Acute leucemia,
  • Severe leukocytosis (>50,000/nl),
  • Severe thrombocytopenia (<5,000/nl),
  • Autoimmune disease with systemic medication of ≥10 mg prednisolone equivalent or previous transplantation,
  • Patients receiving interferon therapy (last 14 days),
  • Patients with known hypersensitivity GM-CSF or known antibodies against GM-CSF, yeast-derived products or any component of the study medication,
  • Ongoing (concomitant) chemotherapy or radiotherapy for malignancy,
  • Acute pulmonary embolism or acute myocardial infarction within last 72 hours,
  • Cardiopulmonary resuscitation within last 7 days,
  • Moribund patient (life expectancy <72 hrs.),
  • Presence of a do-not-resuscitate or do-not-intubate order,
  • Known human immunodeficiency virus (HIV) infection or chronic viral hepatitis
  • Lacking willingness to save and hand out data within the study
  • Accommodation in an institution due to an official or judicial order
  • The informed consent of the patient or the subject's legally acceptable representative can´t be obtained in time
  • Patient has a power of attorney or patient's provision, where he/she refuses participation in any clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Critically ill patients
Intensive care unit patients with refractory septic shock

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of circadian regulation
Time Frame: These parameters are measured during intensive care unit stay, for a maximum of 3 days
Circadian regulation by expression of clock genes
These parameters are measured during intensive care unit stay, for a maximum of 3 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time on mechanical ventilation
Time Frame: They are followed up until the end of intensive care unit stay - or, for a maximum of 28 days
They are followed up until the end of intensive care unit stay - or, for a maximum of 28 days
Intensive care unit length of stay
Time Frame: Participants will be followed for the duration of intensive care stay, an expected average of 4 weeks
Participants will be followed for the duration of intensive care stay, an expected average of 4 weeks
Hospital length of stay
Time Frame: Participants will be followed for the duration of intensive care stay, an expected average of 5 weeks
Participants will be followed for the duration of intensive care stay, an expected average of 5 weeks
Simplified Acute Physiology Score (SOFA II)
Time Frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
Sequential Organ Failure Assessment (SOFA)
Time Frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
Therapeutic Intervention Scoring System (TISS-28)
Time Frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
Mortality
Time Frame: 6 months after intensive care unit discharge
6 months after intensive care unit discharge
Light frequencies
Time Frame: Light frequencies are measured until the end of intensive care unit stay - or, for a maximum of 28 days
Light frequencies are measured until the end of intensive care unit stay - or, for a maximum of 28 days
Light levels (lux)
Time Frame: Light levels are measured until the end of intensive care unit stay - or, for a maximum of 28 days
Light levels are measured until the end of intensive care unit stay - or, for a maximum of 28 days
Cortisol
Time Frame: This parameter is measured in ng/ml during intensive care unit stay, for a maximum of 3 days
This parameter is measured in ng/ml during intensive care unit stay, for a maximum of 3 days
Melatonin
Time Frame: This parameter is measured in pg/ml during intensive care unit stay, for a maximum of 3 days
This parameter is measured in pg/ml during intensive care unit stay, for a maximum of 3 days
Quality of life
Time Frame: Up to 3 and 6 months
Quality of life is measured by SF-36 questionnaire
Up to 3 and 6 months
Cognitive function
Time Frame: Up to 3 and 6 months
Cognitive function is measured by Repeatable Battery for the Assessment of Neuropsychological Status
Up to 3 and 6 months
Multiplex-Genexpression analysis
Time Frame: These parameters are measured during intensive care unit stay, for a maximum of 3 days
Ncounter neuroinflammation and micro rna panel are analysed
These parameters are measured during intensive care unit stay, for a maximum of 3 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nagalase enzyme activity
Time Frame: This parameter is measured at the beginning of the investigation
Nagalase Enzyme activity is expressed in nmol/min per Milliliter. Analysis is evaluated with the perioperative Nagalase results of 10 patients in the clinical trial Phydelio (EudraCT-No 2008-007237-47).
This parameter is measured at the beginning of the investigation
Venous return
Time Frame: This parameter is measured at the beginning of the investigation
Venous return will be assessed after ICU admission by venous return pressure gradient (dVR)
This parameter is measured at the beginning of the investigation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2014

Primary Completion (Actual)

January 21, 2018

Study Completion (Actual)

March 31, 2019

Study Registration Dates

First Submitted

January 20, 2014

First Submitted That Met QC Criteria

January 22, 2014

First Posted (Estimate)

January 24, 2014

Study Record Updates

Last Update Posted (Actual)

June 16, 2020

Last Update Submitted That Met QC Criteria

June 12, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Septic Shock

3
Subscribe